This Week in Cardiology Jan 09 2026 This Week in Cardiology
Jan 9, 2026
Discover the surprising limitations of coronary artery disease anatomy in predicting risks. Dive into the contentious relationship between fish oil supplements and atrial fibrillation, revealing conflicting studies and questions about their safety. Explore the FDA's new nasal drug for paroxysmal supraventricular tachycardia and its potential over traditional approaches. Lastly, learn how vernakalant outshines procainamide in atrial fibrillation conversions, stirring a reflection on regulatory practices and safety.
AI Snips
Chapters
Transcript
Episode notes
Host's Warm New Year Opening
- John opens the episode with a seasonal local color about Kentucky weather and holiday wishes.
- He frames the episode topics as practical clinical takeaways for cardiologists.
Anatomy Adds Little To Risk Prediction
- Coronary CT anatomy adds only modest predictive value over risk scores and CAC for first coronary events.
- CCTA often misclassifies many low-risk people as higher risk while correctly reclassifying few who later have events.
RCTs Show Fish Oil Raises AF Risk
- Randomized trials show a reproducible, dose-related increase in atrial fibrillation with marine omega-3 formulations.
- Observational analyses vary due to analytic flexibility, so RCT signals carry more weight for causation.